Edwards Lifesciences

EWleader

Edwards Lifesciences is the global leader in transcatheter heart valve therapies, particularly TAVR, which has transformed treatment for aortic stenosis from open-heart surgery to a catheter-based procedure.

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($6.4B)

Datos estáticos (cargando finanzas en tiempo real…)

Transcatheter Aortic Valve (60%)

Surgical Structural Heart (15%)

Critical Care (15%)

TMTT (10%)

Composición de segmentos y clientes principales

Detalles del producto

TAVR (SAPIEN)60%

Transcatheter aortic valve replacement systems for heart valve disease

TMTT10%

Transcatheter mitral and tricuspid valve therapies in development

Surgical Structural Heart15%

Surgical heart valves and repair products

Critical Care15%

Hemodynamic monitoring and smart recovery technologies

Relaciones en la Cadena de Suministro

Competidores

Medtronic

CoreValve TAVR system

Impacto: Primary TAVR competitor

Abbott Laboratories

Structural heart portfolio

Impacto: Growing competitor in structural heart

Boston Scientific

ACURATE valve

Impacto: Emerging TAVR competitor

Contexto macro y de mercado

헬스케어Noticias del sector

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Próximos catalizadores

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de Edwards Lifesciences impulsado por IA.

Información de la Empresa

Sede Central

Irvine, California, USA

Fundación

1958

Empleados

20,000+

Sitio Web

edwards.com

Estado del sector — 헬스케어

Noticias del sector